Loading stock data…
Intensity Therapeutics (INTS)
$4.09-0.01 (-0.24%)
Market ClosedLast close Sep 8
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Intensity Therapeutics, Inc. in the Healthcare sector is trading at $4.09 with a market capitalization of $11M. Wall Street consensus targets $19.33 (6 analysts), implying a +372.7% move over the next 12 months. The stock is currently near its 52-week low of $3.51, remaining 37.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +372.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.53M↑ | -$3.14M↓ | -$2.73M↓ | -$2.71M↑ | -$3.39M |
| Net Income | -$2.43M↑ | -$3.05M↓ | -$2.67M↓ | -$2.54M↑ | -$3.35M |
Peer Comparison
JNJUNHPFE
Fundamentals
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.62M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-107.16%
Volume
Today's trading volume
11,641
Recent News
Intensity Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Intensity Therapeutics, Inc.'s Q2 2026 earnings call
Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript
CEO discusses resuming trials and $30M capital needs for Phase 3 sarcoma study.
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why
Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Intensity Therapeutics Inc. (INTS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know
Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).